Lab Bulletin your partner in science

Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, will be showcasing its innovative portfolio of biopharmaceutical technologies and solutions at booth #507 and #509 at the 2010 BioProcess International Conference and Exhibition, 20-24 September at Rhode Island Convention Center, Providence, RI, USA. 

The annual conference and exhibition aims to accelerate and improve biopharmaceutical processes and product development, attracting key personnel from across the bioprocessing industry. At this year's event Novozymes' booth will feature the company's range of regulatory compliant, recombinant and animal-free products and technologies. These innovative solutions offer improved manufacturing efficiency, increased safety and result in superior final products.   

During the five day conference, Novozymes will be presenting two technical posters entitled "Albumin: A robust pharmaceutical excipient in the stabilization of protein therapeutics' and "Application of animal-free recombinant bioactive protein supplements to improve the performance of cell-based viral vaccine production". In addition the company will deliver a presentation on the "Impact of recombinant albumin on the stability of a malarial antigen vaccine". 

Novozymes will also be hosting a workshop on "Improving biomanufacturing efficiency through recombinant solutions". Company experts will discuss how the introduction of innovative technologies and products and ongoing collaborative dialog with the biomanufacturing industry are driving efficiency improvements across the biopharmaceutical lifecycle.  

The company will also be discussing its recent announcement of a 10-year extension to its joint agreement with SAFC^®, a member of the Sigma-Aldrich^® Group. The renewal sees SAFC retain exclusive marketing and distribution rights for Novozymes' LONG ^®R³IGF-I (LONG^®R³) growth factor. 

To learn more about the company's biopharmaceutical technologies and solutions, please visit Novozymes at booth #507 and #509 at the 2010 BioProcess International Conference and Exhibition. Alternatively please visit www.biopharma.novozymes.com